Influence of Heparin and a Low Molecular Weight Heparinoid on Specific Endogenous and Exogenous Fibrinolytic Factors during Rest and Exercise

Summary

The effects of heparin (5,000 IU i.v.) and the low molecular weight heparinoid Org 10172 (Orgaran®) (3,250 anti-Xa units i. v.) on components of the fibrinolytic system were studied in two double-blind, randomised, placebo-controlled, cross-over trials using healthy subjects. In study A (n = 6) the effects were studied during rest and standardized exercise and in study B (n = 6) during a low dose infusion of recombinant tissue-type plasminogen activator (rt-PA; 80 µg over 16 min). At rest, heparin and Org 10172 did not influence the plasma concentrations of endogenous t-PA antigen, and activity, urokinase-type PA (u-PA) antigen, plasmin activatable pro-urokinase (scu-PA), active urokinase (tcu-PA) and plasminogen activator inhibitor-1 (PAI-1) antigen. Recombinant t-PA antigen and activity during rt-PA infusion were also not affected. During exercise, neither heparin nor Org 10172 influenced the area under the curve (AUC) of t-PA and u-PA antigen and t-PA activity when compared with placebo. Unexpectedly, after heparin the AUC of t-PA activity was 49% larger (range +19 to +245%) than after Org 10172 (p <0.05). The last difference was considered spurious. scu-PA, tcu-PA and PAI-1 antigen levels at 2 min after termination of exercise were unaffected by both compounds (p >0.05). Sulphated polysaccharides do not increase fibrinolytic activity of the plasma by changing the concentrations of the components of the fibrinolytic system.

• REFERENCES

• 1 Mantovani M, Prino G. Inhibitory effect of Ateroid® on rat serum antiplasmin activity. Eur J Pharmacol 1970; 13: 108-112
• 2 Kudrjashov BA, Liapina LA, Uljanov AM. Complex fibrinogen-heparin (FH) and fibrinogen degradation products (FDP) in blood of rats after intravenous injection of thrombin. Thromb Res 1978; 13: 397-407
• 3 Rothschild Z, Batarra SP, Polizello ACM. Proteases of bovine plasma activated by sulfated polysaccharides. Thromb Res 1983; 31: 187-193
• 4 Pâques EP, Stöhr HA, Heimburger N. Study on the mechanism of action of heparin and related substances on the fibrinolytic system: relationship between plasminogen activators and heparin. Thromb Res 1986; 42: 797-807
• 5 Takada Y, Takada A. Influence of dextran sulfate and tranexamic acid on the activation of plasminogen by urokinase. Thromb Res 1979; 16: 865-869
• 6 Kumada T, Abiko Y. Fibrinolytic action of a new semi-synthetic polysaccharide sulphate, galactan polysulphate (DH 6322) in the rat. Thromb Res 1985; 39: 09-19
• 7 Kumar S, Panagakos F. Stimulation of plasminogen activator catalyzed plasminogenolysis by heparin and heparan sulphate. Fet Proc 1987; 46: 2271 (Abstr)
• 8 Dosne AM, Benbetowicz AV, Kher A, Samama M. Marked potentiation of the plasminogenolytic activity of pro-urokinase by unfractionated heparin and a low molecular-weight heparin. Thromb Res 1988; 51: 627-630
• 9 Lijnen HR, Collen D. Stimulation by heparin of the plasmin-mediated conversion of single-chain to two-chain urokinase-type plasminogen activator. Thromb Res 1986; 43: 687-690
• 10 Doutremepuich C, Gestreau JL, Kuttler C, Fenelon L, Toulemonde F, Vairel EG, Quilichini R. Fibrinolytic activity of heparin and heparin fractions. Haemostasis 1984; 14: 119 (Abstr)
• 11 Lackner H, Merskey C. Variation in fibrinolytic activity after acute myocardial infarction and after the administration of oral anticoagulant drugs and intravenous heparin. Br J Haematol 1960; 6: 402-413
• 12 Arnesen H, Engebretsen LF, Ugland OM, Seljeflot I, Kierulf P. Increased fibrinolytic activity after surgery induced by low dose heparin. Thromb Res 1987; 45: 553-559
• 13 Melissari E, Scully MF, Paes T, Kakkar VV. The influence of LMW heparin on the coagulation and fibrinolytic response to surgery. Thromb Res 1985; 37: 115-126
• 14 Klein P. Plasma levels of t-PA:Ag under standard heparin therapy. Thromb Res 1989; 56: 649-653
• 15 Vairel EG, Bouty-Boye H, Toulemonde F, Doutremepuich C, Marsch NA, Gaffney PJ. Heparin and a low molecular weight fraction enhances thrombolysis and by this pathway exercises a protective effect against thrombosis. Thromb Res 1983; 30: 219-224
• 16 Agnelli G, Borm J, Cosmi B, Levi M, Ten Cate JW. Effects of standard heparin and a low molecular weight heparin (Kabi 2165) on fibrinolysis. Thromb Haemostas 1988; 60: 311-313
• 17 Fischer AM, Merton RE, Marsh NA, Williams S, Gaffney PJ, Barrowcliffe TW, Thomas DP. A comparison of pentosan polysulphate and heparin. II. Effects of subcutaneous injection. Thromb Haemostas 1982; 47: 109-113
• 18 Marsh NA, Born GVR. In vivo and in vitro effects of low molecular weight heparan sulphate on the human fibrinolytic enzyme system. Blood Coagulation Fibrinolysis 1991; 2: 453-458
• 19 Vinazzer H, Stemberger A, Haas S, Blümel G. Influence of heparin; of different heparin fractions and of a low molecular weight heparin-like substance on the mechanism of fibrinolysis. Thromb Res 1982; 27: 341-352
• 20 Holemans R, Adamis D, Horace JF. Interaction of heparin with fibrinolysis. Thromb Diath Haemorrh 1963; 9: 447-458
• 21 Bounameaux H, Lijnen HR, Hellemans H, Verstraete M. Effect of standard and low-molecular weight heparin fractions on fibrinolysis and platelet aggregation in patients undergoing hysterectomy. Thromb Haemostas 1986; 55: 298
• 22 Eriksson E, Wollter IM, Christenson B, Stigendal L, Risberg B. Heparin and fibrinolysis - comparison of subcutaneous administration of unfractionated and low molecular weight heparin. Thromb Haemostas 1988; 59: 284-288
• 23 Neerstrand H, Ostergard P, Bergqvist D, Mätzsch T, Hedner U. tPA inhibitor, tPA:Ag, plasminogen, and α₂-antiplasmin after low molecular weight heparin or standard heparin. Fibrinolysis. 1987; 1: 39-43
• 24 Marsch N. Does heparin stimulate fibrinolysis? Br J Haematol. 1990; 76: 163-167
• 25 Martin M. The fibrinolytic effect of euglobulin fraction for human plasma before and after addition of an acid polysaccharide (SP 54). In: Synthetic Fibrinolytic and Thrombolytic Agents. Von Kaulla KN, Davidson JF, Charles CT. (eds) Springfield, IL.: 1975. pp 276-283
• 26 Prino G, Mantovani M. The in vitro effect of Ateroid® on the fibrinolytic activity of rat euglobulins. Eur J Pharmacol 1969; 6: 190-192
• 27 Astrup T, Rosa AT. A plasminogen pro-activator system in human blood effective in absence of Hageman factor. Thromb Res 1974; 4: 609-613
• 28 Marsch N, Gaffney P. Some observations on the release of extrinsic and intrinsic plasminogen activators during exercise in man. Haemostasis 1980; 9: 238-247
• 29 Fortuin NJ. Exercise stress testing. Circulation 1977; 56: 699-712
• 30 Manual Biopool Imulyse™ 5 t-PA Kit for determination of human tissue plasminogen activator antigen in plasma and biological fluids.
• 31 Binnema DJ, Iersel JJL, Dooijewaard G. Quantitation of urokinase antigen in plasma and cultured media by use of an ELISA. Thromb Res 1986; 43: 569-577
• 32 Manual Biopool TintElize™PAI-l Enzyme immunoassay for determination of human plasminogen activator inhibitor 1.
• 33 Verheijen JH, Mullart E, Chang GTG, Kluft C, Wijngaards G. A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurement in plasma. Thromb Haemostas 1982; 48: 266-269
• 34 Gaffney PJ, Curtis AD. A collaborative study of a proposed International Standard for tissue plasminogen activator (t-PA). Thromb Haemostas 1985; 53: 134-136
• 35 Dooijewaard G, De Boer A, Turion PNC, Cohen AF, Breimer DD, Kluft C. Physical exercise induces enhancement of urokinase-type plasminogen activator (u-PA) levels in plasma. Thromb Haemostas 1991; 65: 82-86
• 36 Teien AN, Lie M. Evaluation of an amidolytic heparin assay method: increased sensitivity by adding purified antithrombin-III. Thromb Res 1978; 10: 399-410
• 37 Larsen ML, Abildgaard U, Teien AN, Gjesdal K. Assay of plasma heparin using thrombin and the chromogenics substrate H-D-Phe-Pip-Arg-pNA (S-2238). Thromb Res 1978; 13: 285-288
• 38 Marder VJ. A simple technique for the measurement of plasma heparin concentration during anticoagulant therapy. Thromb Diath Haemorrh 1970; 24: 230-239
• 39 Biggs R. Human Blood Coagulation, Haemostasis and Thrombosis. 2nd ed. Blackwell Scientific Publications, Oxford: 1972
• 40 Andreotti F, Davies GJ, Hackett DR, Khan MI, De Bart ACW, Dooijewaard G, Maseri A, Kluft C. Circadian variation of fibrinolytic factors in normal human plasma. Fibrinolysis 1988; 2: 90-92
• 41 Vinazzer H, Woler M. A new low molecular weight heparin fragment (PK 10169): in vitro and in vivo studies. Thromb Res 1985; 40: 135-146
• 42 Agnelli G, Levi M, Cosmi B, Ten Cate JW, Nenci GG. Additive effect of dDAVP and standard heparin in increasing plasma t-PA. Thromb Haemostas 1989; 61: 507-510
• 43 De Boer A, Kluft C, Kasper FJ, Kroon JM, Schoemaker HC, Breimer DD, Soons PA, Emeis JJ, Pruis J, Cohen AF. The clearance of recombinant human tissue-type plasminogen activator is dependent on liver blood flow. Thromb Haemostas 1992; 67: 83-87
• 44 De Boer A, Kluft C, Cohen AF. Life style and blood fibrinolytic activity: a comment of clearance of plasminogen activators. Fibrinolysis 1990; 4: 61-63